XORTX Therapeutics Inc (XRTX.V)
TSXV · CAD · Healthcare · Biotechnology
CA$3.19 (+0.00%) as of
Key statistics
- Market cap
- 5.79M
- Forward P/E
- 2.90
- EPS (TTM)
- -3.5900
- 52-week range
- 2.4250 – 9.8500
- Beta
- 0.08
- Profit margin
- 0.00%
- Volume
- 880.00
About XORTX Therapeutics Inc
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Calgary, AB, Canada
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.